AstraZeneca Discontinues Late-Stage Trial for Metastatic Lung Cancer Drug

Source Summary

AstraZeneca is discontinuing a late-stage drug trial in patients with metastatic non-small cell lung cancer, continuing a series of recent setbacks for the company.